Clinical Trial Search

Primary: Role of Essential Oil Therapy in Environmental Diffusion as a Complement of Psychotropic Drugs in the Management of Psychological and Behavioral Disorders (BPSD)…

Primary: Neuropsychiatric Inventory Questionnaire Average Score During Hospital Admission — 5.36; 3.87 score on a scale

Primary: Change in Approaches to Dementia Questionnaire (ADQ) Total Score From Baseline to 3 Months — -1.8; -2.3 units on a scale

Primary: Physical Function as Determined by Barthel Index — 35.82; 31.36; 33.63; 33.93 score on a scale

Primary: Evaluations of Behavioral Disorders — 68; 66; 36; 69 Scores on a scale — p=1

Primary: Change in Neuropsychiatric Inventory (NPI) — -32.79 units on a scale

Primary: Success Rate of Adherence — 2; 6; 7 Participants — p=0.12

Primary: Revised Memory and Behavior Problems Checklist — 0.66; 0.89 units on a scale

Primary: Brief Center for Epidemiologic Studies Depression Scale (CESD) — -3.46; -1.26 units on a scale — p=.039

Primary: Number of Participants With Aggression as Determined by the Cohen-Mansfield Agitation Inventory (Aggression Subscale) — 8; 14; 9; 17 participants — p=0.13

Primary: Change in Quality of Life-Alzheimer's Disease Score — 12.32; 15.88 score on a scale

Primary: Change in Global Cognitive Function as Assessed by the Wechsler Memory Scale-III — -0.2; -0.2 score on a scale

Primary: Unified Parkinson Disease Rating Scale (UPDRS). — 12; 12; 10; 10 units on a scale

Primary: Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change — 2.5; 2.43 units on a scale

Primary: Change in Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog) — 5.8; -7.2; 4.8 units on the ADAS-cog scale

Primary: 12-Month Cumulative Incidence of ADRD Diagnoses — 213; 134; 355 Number of new ADRD cases — p=0.006

Primary: Percentage of Participants With an Emergency Department (ED) Visit Within 6 Months After Enrollment — 41.60; 39.40 percentage of participants

Primary: Symptoms of Agitation as Measured by the Pittsburgh Agitation Scale — 7.14; 5.55; 5.69; 4.97 score on a scale — p=.015

Primary: Falls, Accidents, and Injuries — 141; 115 participants — p=0.4170

Primary: Dispensing of Psychotropic Medications — 161; 315 Participants — p=0.492

Primary: Number of Participants With Aggression as Per the Cohen Mansfield Agitation Inventory, Aggression Subscale — 29; 23 Participants — p=0.29

Primary: Change in Patient Quality of Life as Measured by the EuroQol 5-D (EQ-5D) Scale Between Baseline (Visit 1) and 1 Year (Visit 4) — 1; 0.5; 0.5; 0 units on a scale — p=0.59

Primary: Change of C3 Activation (NPS-shared Neural Circuit Measure — -0.15; 0.01 change of arbitrary unit LPG activation — p=<0.05

Primary: Change From Baseline to Week 16 in Modified Functional Status Questionnaire (mFSQ) Total Score — 14.0 score on a scale — p=<0.0001

Primary: Change in Agitation and Aggression as Measured by the Neuropsychiatric Inventory Scale (NPI) — 7.14; 5.75 score on a scale

Primary: Acceptability of the tDCS Treatment as Assessed by the tDCS Acceptability Questionnaire

Primary: ICIQ-OAB Questionnaire — 5.5; 5.8 score on a scale

Primary: Association Between Basal Ganglia Beta Power and Effort Level (Beta Coefficient) — -0.175 beta coefficient — p=0.007

Primary: Change in Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score — 3.2; 2.5 score on a scale — p=0.53

Primary: Participation Rate — 84 Participants